Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Efstathiou, Jason A
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. [electronic resource] - European urology Oct 2008 - 816-23 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
0302-2838
10.1016/j.eururo.2008.01.021 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal--adverse effects
Cardiovascular Diseases--mortality
Flutamide--adverse effects
Goserelin--adverse effects
Humans
Male
Middle Aged
Multivariate Analysis
Prostatic Neoplasms--drug therapy
Time Factors
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. [electronic resource] - European urology Oct 2008 - 816-23 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
0302-2838
10.1016/j.eururo.2008.01.021 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal--adverse effects
Cardiovascular Diseases--mortality
Flutamide--adverse effects
Goserelin--adverse effects
Humans
Male
Middle Aged
Multivariate Analysis
Prostatic Neoplasms--drug therapy
Time Factors